PT-141, also known as bremelanotide, is a cyclic peptide studied through melanocortin-receptor binding, signaling, and structure–activity research.
PT-141 is a cyclic melanocortin peptide derived from the Melanotan-II scaffold. Its laboratory identity is best understood through the melanocortin receptor family, a group of G-protein-coupled receptors whose ligand recognition depends strongly on peptide sequence and conformation.
Published research has compared the binding and functional activity of melanocortin peptides across receptor subtypes, using radioligand, cyclic-AMP, calcium, and structure–activity assays. This work shows why receptor subtype, cell background, and endpoint selection matter: a peptide can display different apparent potency or signaling behavior across assay systems.
These studies examine melanocortin ligand recognition and downstream signaling in controlled laboratory systems. The sources below do not establish safety, efficacy, dosing, administration, or an expected outcome for a VIVO product.
Peer-reviewed sources for the research summarised above. VIVO summarises published, third-party science and does not conduct or sponsor this research.